Amended Statement of Beneficial Ownership (3/a)
October 07 2021 - 4:08PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Lazer Dean |
2. Date of Event Requiring Statement (MM/DD/YYYY)
9/14/2021
|
3. Issuer Name and Ticker or Trading Symbol
Pasithea Therapeutics Corp. [KTTA]
|
(Last)
(First)
(Middle)
1111 LINCOLN ROAD, SUITE 500 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner _____ Officer (give title below) ___X___ Other (specify below) / Not a 10% owner |
(Street)
MIAMI BEACH, FL 33139
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY) 9/14/2021
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 902600 | I | See Footnote (1) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | This Form 3 was originally and incorrectly filed to disclose Dean Lazer as a 10% holder, specifically owning 902,600 shares of Common Stock through DPL Capital Inc. ("DPL"). Mr. Lazer is the President of DPL and has sole voting and investment control with respect to the shares held by DPL. As such, Mr. Lazer may be deemed to beneficially own the shares held directly by DPL. At this time, the 902,600 shares of Common Stock held by DPL represent less than 10% of the Common Stock. This amended Form 3/A discloses that Mr. Lazer is not a 10% holder. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Lazer Dean 1111 LINCOLN ROAD, SUITE 500 MIAMI BEACH, FL 33139 |
|
|
| Not a 10% owner |
Signatures
|
/s/ Dean Lazer | | 10/7/2021 |
**Signature of Reporting Person | Date |
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Sep 2023 to Sep 2024